To the full analysis
Buyback calculator for Alnylam Pharmaceuticals
Alnylam Pharmaceuticals stock: dividend
ALNYAlnylam Pharmaceuticals does not currently pay a dividend. Alnylam Pharmaceuticals did not buy back any of its own shares from fiscal 2023 to 2025.
Whether Alnylam Pharmaceuticals, Inc. pays a dividend and what the company does with its cash instead: free cash flow, buybacks of its own shares and the share count over recent years.
Daily figure as of 12 Nov 2026
Free cash flow and buybacks
| Fiscal year | Free cash flow | Share buybacks | Shares outstanding |
|---|---|---|---|
| 2025 | $465.38M | $0 | 131.00M |
| 2024 | −$42.59M | $0 | 127.65M |
| 2023 | $41.95M | $0 | 124.91M |
| 2022 | −$613.33M | $0 | 121.69M |
| 2021 | −$718.07M | $0 | 118.45M |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 13 Feb 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.